JP2021535161A5 - - Google Patents
Info
- Publication number
- JP2021535161A5 JP2021535161A5 JP2021510984A JP2021510984A JP2021535161A5 JP 2021535161 A5 JP2021535161 A5 JP 2021535161A5 JP 2021510984 A JP2021510984 A JP 2021510984A JP 2021510984 A JP2021510984 A JP 2021510984A JP 2021535161 A5 JP2021535161 A5 JP 2021535161A5
- Authority
- JP
- Japan
- Prior art keywords
- hae
- antibody
- treatment period
- weeks
- composition
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024094996A JP2024113183A (ja) | 2018-08-30 | 2024-06-12 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725216P | 2018-08-30 | 2018-08-30 | |
| US62/725,216 | 2018-08-30 | ||
| US201962808612P | 2019-02-21 | 2019-02-21 | |
| US62/808,612 | 2019-02-21 | ||
| PCT/US2019/048961 WO2020047352A1 (en) | 2018-08-30 | 2019-08-30 | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094996A Division JP2024113183A (ja) | 2018-08-30 | 2024-06-12 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021535161A JP2021535161A (ja) | 2021-12-16 |
| JP2021535161A5 true JP2021535161A5 (https=) | 2022-09-05 |
| JPWO2020047352A5 JPWO2020047352A5 (https=) | 2022-09-05 |
| JP7585193B2 JP7585193B2 (ja) | 2024-11-18 |
Family
ID=67953889
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510984A Active JP7585193B2 (ja) | 2018-08-30 | 2019-08-30 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
| JP2024094996A Pending JP2024113183A (ja) | 2018-08-30 | 2024-06-12 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094996A Pending JP2024113183A (ja) | 2018-08-30 | 2024-06-12 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200109214A1 (https=) |
| EP (1) | EP3843840A1 (https=) |
| JP (2) | JP7585193B2 (https=) |
| KR (1) | KR20210053928A (https=) |
| CN (1) | CN113056304A (https=) |
| AU (2) | AU2019328324B2 (https=) |
| BR (1) | BR112021003789A2 (https=) |
| CA (1) | CA3110689A1 (https=) |
| IL (1) | IL281063A (https=) |
| MA (1) | MA53490A (https=) |
| MX (1) | MX2021002349A (https=) |
| WO (1) | WO2020047352A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3459564B1 (en) | 2010-01-06 | 2021-10-27 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
| CA2823776A1 (en) | 2011-01-06 | 2012-07-12 | Dyax Corp. | Plasma kallikrein binding proteins |
| WO2014152232A2 (en) | 2013-03-15 | 2014-09-25 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| AU2015209481C1 (en) | 2014-01-21 | 2020-10-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
| IL295414B2 (en) | 2014-03-27 | 2026-02-01 | Takeda Pharmaceuticals Co | Compositions and methods for treating macular edema due to diabetes |
| AU2016366557B2 (en) | 2015-12-11 | 2024-01-25 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| US20200109214A1 (en) * | 2018-08-30 | 2020-04-09 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| US12528880B2 (en) | 2020-01-13 | 2026-01-20 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| PT739355E (pt) | 1994-01-11 | 2005-01-31 | Dyax Corp | Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| WO2003103475A2 (en) | 2002-06-07 | 2003-12-18 | Dyax Corp. | Prevention and reduction of blood loss |
| CA2823776A1 (en) * | 2011-01-06 | 2012-07-12 | Dyax Corp. | Plasma kallikrein binding proteins |
| WO2014152232A2 (en) * | 2013-03-15 | 2014-09-25 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| IL295414B2 (en) * | 2014-03-27 | 2026-02-01 | Takeda Pharmaceuticals Co | Compositions and methods for treating macular edema due to diabetes |
| BR112017020864A2 (en) * | 2015-03-30 | 2018-07-10 | Dyax Corp. | plasma kallikrein inhibitors and their uses for the prevention of hereditary angioedema attack |
| AU2016366557B2 (en) | 2015-12-11 | 2024-01-25 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| TW201727079A (zh) * | 2015-12-18 | 2017-08-01 | 葛萊兒明尼蘇達股份有限公司 | 波紋管安裝及保留方法 |
| US20200109214A1 (en) * | 2018-08-30 | 2020-04-09 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
-
2019
- 2019-08-30 US US16/556,524 patent/US20200109214A1/en not_active Abandoned
- 2019-08-30 MA MA053490A patent/MA53490A/fr unknown
- 2019-08-30 AU AU2019328324A patent/AU2019328324B2/en active Active
- 2019-08-30 BR BR112021003789-6A patent/BR112021003789A2/pt unknown
- 2019-08-30 WO PCT/US2019/048961 patent/WO2020047352A1/en not_active Ceased
- 2019-08-30 JP JP2021510984A patent/JP7585193B2/ja active Active
- 2019-08-30 EP EP19768977.1A patent/EP3843840A1/en active Pending
- 2019-08-30 CA CA3110689A patent/CA3110689A1/en active Pending
- 2019-08-30 CN CN201980072190.9A patent/CN113056304A/zh active Pending
- 2019-08-30 MX MX2021002349A patent/MX2021002349A/es unknown
- 2019-08-30 KR KR1020217009365A patent/KR20210053928A/ko not_active Ceased
-
2021
- 2021-02-23 IL IL281063A patent/IL281063A/en unknown
-
2022
- 2022-05-16 US US17/745,770 patent/US20230104754A1/en active Pending
-
2024
- 2024-06-12 JP JP2024094996A patent/JP2024113183A/ja active Pending
-
2025
- 2025-09-15 AU AU2025230807A patent/AU2025230807A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021535161A5 (https=) | ||
| JP2022033868A5 (https=) | ||
| US20240052058A1 (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| JP2019501886A5 (https=) | ||
| JP2024113183A5 (https=) | ||
| JP2020002171A5 (https=) | ||
| TWI837532B (zh) | 治療潰瘍性結腸炎之方法 | |
| JP2018514510A5 (https=) | ||
| Reisch et al. | Use of angiotensin-converting enzyme inhibitors for the preservation of kidney function | |
| JP2019514974A5 (https=) | ||
| WO2023144699A1 (en) | Methods for treatment of subjects with plaque psoriasis of the scalp | |
| Takeuchi et al. | OP0040 adding tocilizumab or switching to tocilizumab monotherapy in RA patients with inadequate response to methotrexate: 24-week results from a randomized controlled study (Surprise Study) | |
| JP2021523138A5 (https=) | ||
| JPWO2020047352A5 (https=) | ||
| UA127588C2 (uk) | Способи застосування та композиції, які містять дулаглутид | |
| JPWO2020186132A5 (https=) | ||
| KR20170118830A (ko) | 조현병의 치료를 위한 일로페리돈 | |
| US20250345418A1 (en) | Methods of treating al amyloidosis | |
| NZ783274B2 (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| JPWO2021146160A5 (https=) | ||
| NZ783274A (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| Dall'Era et al. | FC 035 VOCLOSPORIN INCREASES RENAL RESPONSE AT COMMONLY USED UPCR THRESHOLDS IN PATIENTS WITH LUPUS NEPHRITIS | |
| US20210338766A1 (en) | Methods of treating multiple myeloma | |
| RU2021129732A (ru) | Ингибиторы плазменного калликреина и их применение для лечения приступа наследственного ангионевротического отека | |
| Conner et al. | Gastrointestinal adverse events related to study drug and leading to discontinuation through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials |